73 related articles for article (PubMed ID: 2647294)
1. Randomized trial of recombinant alpha 2b-interferon with or without indomethacin in patients with metastatic malignant melanoma.
Miller RL; Steis RG; Clark JW; Smith JW; Crum E; McKnight JE; Hawkins MJ; Jones MJ; Longo DL; Urba WJ
Cancer Res; 1989 Apr; 49(7):1871-6. PubMed ID: 2647294
[TBL] [Abstract][Full Text] [Related]
2. Phase I clinical trial of interleukin 2 and alpha-interferon: toxicity and immunologic effects.
Budd GT; Osgood B; Barna B; Boyett JM; Finke J; Medendorp SV; Murthy S; Novak C; Sergi J; Tubbs R
Cancer Res; 1989 Nov; 49(22):6432-6. PubMed ID: 2804986
[TBL] [Abstract][Full Text] [Related]
3. Eastern cooperative group trial of interferon gamma in metastatic melanoma: an innovative study design.
Schiller JH; Pugh M; Kirkwood JM; Karp D; Larson M; Borden E
Clin Cancer Res; 1996 Jan; 2(1):29-36. PubMed ID: 9816086
[TBL] [Abstract][Full Text] [Related]
4. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
[TBL] [Abstract][Full Text] [Related]
6. A phase I trial of recombinant interferon-alpha and alpha-difluoromethylornithine in metastatic melanoma.
Croghan MK; Booth A; Meyskens FL
J Biol Response Mod; 1988 Aug; 7(4):409-15. PubMed ID: 3139843
[TBL] [Abstract][Full Text] [Related]
7. Phase II clinical trial of combined natural interferon-beta plus recombinant interferon-gamma treatment of chronic hepatitis B.
Musch E; Högemann B; Gerritzen A; Fischer HP; Wiese M; Kruis W; Malek M; Gugler R; Schmidt G; Huchzermeyer H; Gerlach U; Dengler HJ; Sauerbruch T
Hepatogastroenterology; 1998; 45(24):2282-94. PubMed ID: 9951911
[TBL] [Abstract][Full Text] [Related]
8. [Tolerance and feasibility of adjuvant treatment of stage II malignant melanoma with high-dose interferon-alpha].
Bédane C; Le Brun V; Boulinguez S; Berdah JF; Bouyssou ML; Delpuget N; Bernard P; Tubiana-Mathieu N; Bonnetblanc JM
Ann Dermatol Venereol; 1999 Feb; 126(2):142-6. PubMed ID: 10352829
[TBL] [Abstract][Full Text] [Related]
9. A phase I study of recombinant interleukin 2 plus recombinant beta-interferon.
Krigel RL; Padavic-Shaller KA; Rudolph AR; Litwin S; Konrad M; Bradley EC; Comis RL
Cancer Res; 1988 Jul; 48(13):3875-81. PubMed ID: 3132324
[TBL] [Abstract][Full Text] [Related]
10. Preliminary observations of immunomodulatory activity of lymphoblastoid interferon-alpha administered every other day or weekly.
Neefe JR; Sullivan JE; Silgals R
J Biol Response Mod; 1983; 2(5):441-9. PubMed ID: 6644348
[TBL] [Abstract][Full Text] [Related]
11. NTP Toxicology and Carcinogenesis Studies of AZT (CAS No. 30516-87-1) and AZT/alpha-Interferon A/D B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1999 Feb; 469():1-361. PubMed ID: 12579204
[TBL] [Abstract][Full Text] [Related]
12. Clinical phase II trial of recombinant DNA interferon (interferon alpha 2b) in patients with metastatic malignant melanoma.
Dorval T; Palangie T; Jouve M; Garcia-Giralt E; Israel L; Falcoff E; Schwab D; Pouillart P
Cancer; 1986 Jul; 58(2):215-8. PubMed ID: 3719515
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of chemoneuroimmunotherapy with platinum, subcutaneous low-dose interleukin-2 and the pineal neurohormone melatonin (P.I.M.) as a second-line therapy in metastatic melanoma patients progressing on dacarbazine plus interferon-alpha.
Lissoni P; Vaghi M; Ardizzoia A; Malugani F; Fumagalli E; Bordin V; Fumagalli L; Bordoni A; Mengo S; Gardani GS; Tancini G
In Vivo; 2002; 16(2):93-6. PubMed ID: 12073777
[TBL] [Abstract][Full Text] [Related]
14. Pilot study of high-dose, concurrent biochemotherapy for advanced melanoma.
Kim KB; Eton O; East MJ; Hodges C; Papadopoulos NE; Grimm EA; Bedikian AY
Cancer; 2004 Aug; 101(3):596-603. PubMed ID: 15274073
[TBL] [Abstract][Full Text] [Related]
15. Parameters of interferon action: II. Immunological effects of recombinant leukocyte interferon (IFN-alpha 2) in phase I-II trials.
Ernstoff MS; Fusi S; Kirkwood JM
J Biol Response Mod; 1983; 2(6):540-7. PubMed ID: 6607324
[TBL] [Abstract][Full Text] [Related]
16. Treatment of metastatic malignant melanoma with recombinant interferon alpha 2.
Robinson WA; Mughal TI; Thomas MR; Johnson M; Spiegel RJ
Immunobiology; 1986 Sep; 172(3-5):275-82. PubMed ID: 3804370
[TBL] [Abstract][Full Text] [Related]
17. Suppressor cell activity in a randomized trial of patients receiving active specific immunotherapy with melanoma cell vaccine and low dosages of cyclophosphamide.
Hoon DS; Foshag LJ; Nizze AS; Bohman R; Morton DL
Cancer Res; 1990 Sep; 50(17):5358-64. PubMed ID: 2143687
[TBL] [Abstract][Full Text] [Related]
18. [Therapeutic response of interferon-beta in malignant melanoma].
Ishihara K
Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 1):1010-6. PubMed ID: 2421645
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial of natural human interferon beta in metastatic malignancy.
Bukowski RM; Sergi JS; Sharfman WJ; Budd GT; Murthy S; Barna B; Medendorp SV; Yen-Lieberman B; Gibson V; Bauer L
Cancer Res; 1991 Feb; 51(3):836-40. PubMed ID: 1988123
[TBL] [Abstract][Full Text] [Related]
20. Recombinant alpha-interferon therapy in multiple myeloma.
Anand AS; Shah PM; Parikh BJ; Shah SA; Patel KM; Shukla SN; Talati SS; Patel AR
Indian J Cancer; 1990 Dec; 27(4):203-7. PubMed ID: 2090574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]